PRA Health Sciences Inc (NASDAQ:PRAH) Given Consensus Rating of “Hold” by Brokerages

PRA Health Sciences Inc (NASDAQ:PRAH) has received a consensus recommendation of “Hold” from the fourteen research firms that are covering the company, MarketBeat reports. Nine research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $100.82.

Several equities analysts recently commented on the company. Mizuho cut their target price on PRA Health Sciences from $95.00 to $82.00 and set a “neutral” rating for the company in a research report on Friday, April 3rd. Zacks Investment Research raised PRA Health Sciences from a “sell” rating to a “hold” rating and set a $99.00 price objective for the company in a report on Tuesday, May 19th. Robert W. Baird lowered their target price on shares of PRA Health Sciences from $106.00 to $101.00 and set an “outperform” rating on the stock in a report on Monday, May 4th. BidaskClub cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Finally, Citigroup reduced their price target on shares of PRA Health Sciences from $120.00 to $90.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th.

In other news, CFO Michael J. Bonello sold 3,672 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $87.97, for a total transaction of $323,025.84. Following the sale, the chief financial officer now directly owns 23,328 shares of the company’s stock, valued at $2,052,164.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Amundi Pioneer Asset Management Inc. lifted its stake in PRA Health Sciences by 338.1% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 6,997 shares of the medical research company’s stock valued at $772,000 after purchasing an additional 5,400 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of PRA Health Sciences by 7.3% during the 4th quarter. Victory Capital Management Inc. now owns 47,530 shares of the medical research company’s stock worth $4,815,000 after acquiring an additional 3,229 shares during the last quarter. Royce & Associates LP acquired a new position in shares of PRA Health Sciences during the 4th quarter worth approximately $1,106,000. Sei Investments Co. raised its stake in PRA Health Sciences by 36.1% in the 4th quarter. Sei Investments Co. now owns 72,514 shares of the medical research company’s stock valued at $8,061,000 after acquiring an additional 19,246 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new stake in PRA Health Sciences during the 4th quarter valued at $153,000. Institutional investors own 98.27% of the company’s stock.

PRA Health Sciences stock traded up $0.08 on Friday, hitting $94.18. The company’s stock had a trading volume of 752,112 shares, compared to its average volume of 408,702. The company has a fifty day moving average price of $97.78 and a 200-day moving average price of $97.16. The firm has a market cap of $6.00 billion, a P/E ratio of 25.73 and a beta of 1.09. PRA Health Sciences has a one year low of $58.67 and a one year high of $113.32. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 1.30.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Thursday, April 30th. The medical research company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.04. The business had revenue of $783.71 million for the quarter, compared to analysts’ expectations of $749.61 million. PRA Health Sciences had a net margin of 7.66% and a return on equity of 27.59%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.10 earnings per share. Analysts anticipate that PRA Health Sciences will post 3.65 EPS for the current year.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: What are the risks of holding treasury bonds?

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.